QI Update
Product Planning Update
MPOG Annual Retreat
October 2, 2020
Disclosures
• No personal consulting, financial, or board membership with any
company
• I am a PI/Co-I on projects that receive grant funding from
• Blue Cross Blue Shield of Michigan
• Apple, Inc
• NIH
• Edwards Lifesciences
Objectives
• 2019 QI Plan Reflection
• Describe MPOG Product Planning Process
• Application Development 2020
• Plans for 2021 and beyond
• Out by 2:30 ET
Please feel free to ask questions or
provide feedback at any point by
unmuting yourself or via Zoom chat
MPOG
Research
Quality Improvement
(ASPIRE)
Reflection
What We Said in 2019 What We Did in 2020
Focus on measures that need to be
addressed on a systems level
Mort 01
– 30 day in hospital
mortality
Evolve our attribution philosophy
from “failed” case to “flagged” case
Changed verbiage
on QI reporting
tools to “passed” and “flagged”
Allow
modification of MIPS/ former
QCDR measures
Modified these measures based on
Quality Committee feedback
Create
a formal measure review
process
Created ASPIRE
Measure Review
Schedule and assigned measures
to
Quality Champions
Measures/Data
that we said we
would build in 2019
What
did we do in 2020?
Glycemic management
GLU 03, O4 (glycemic
management measures
including PACU data)
Include
transfusion management
data from PACU
Pending
Hypotension risk adjustment
Pending
SUS 02 (Sustainability)
Pending
Understand AKI better
Developed
AKI Toolkit
Pediatric/
OB Anesthesia Measures
Temp
04-Peds, OME (T&A), ABX-01-OB
Sugammadex
Data
Sugammadex
data presented at July ASPIRE meeting
Reflection
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47
Sugammadex or Neostigmine across MPOG?
Our QI Plan for 2021
GLU 05, 06
Hyperglycemia treatment
and appropriate Preop
glucose check
SUS 02
GWF inhalational agents
PUL 04
Respiratory bundle
Peds + OB + Cardiac subcommittee recommended measures
More informational/best practice measures (ASPIRE 2.0)
Registry Outcomes on QI Reporting (MSQC, NSQIP, STS, etc)
MPOG QI Stories at Quality Committee Meetings
MPOG Product Planning Update
Product Planning Themes
• Ability to easily access data that you
submit
• Turn the data that you submit into
usable information
• Self-service
• Build tools that enable both research
and QI missions
• Where not possible, balance QI and
Research development
• Stay agile so we can pivot quickly where
needed
How we organize product development
Category
Examples
App Suite
Data Diagnostics, Transfer Utility, Variable Mapping
Data types
Microbiology, Registry integration
(STS, MTQIP, MSQC, MVC)
Infrastructure
Server migration, import manager
updates
QI Measures
GLU 03, ABX 01
– OB, TEMP 04 – PEDS
Computed Phenotypes
Anesthesia Technique, Baseline BP,
Elixhauser Comorbidities
Major Applications
DataDirect
, QI Reporting
Minor Applications
Phenotype Browser, Measure Browser
Participating Sites
New sites, import
manager conversions, local database upgrades
2019 – 2020 Development
Measure Browser
DataDirect 2.0
QI Reporting
CaseViewer 2.0
DataDirect 2.1
Intuitive
Categories
Data Driven
Filters
Overhauled
Outputs
CaseViewer 2.0
CaseViewer 2.0
Removed banner
clutter
Curated views
Enhanced Search
Intra-case Search
Updated
organization
QI Reporting
Updated Filters
Specialty
Dashboards
One click
navigation
Improved
visualizations
Measure labels
QI Reporting
Updated
Benchmarking
Intra-institutional
comparison
2021 Development Plans
• Emails 2.0
• Incremental updates to DataDirect
and QI Reporting
• App suite: Location Mapping
overhaul
• MQUARK: generalize clinical trial
software
• Infrastructure: more computed
phenotypes
MPOG REGISTRY
Goal: Apps that work together better
Discussion
• Are we on the right track?
• Are the development priorities the right ones?
• What is missing?
• What is overemphasized?
See you next year (in person)!
Thank You
